Enanta Pharmaceuticals Inc (ENTA)

NASDAQ
71.47
+0.22(+0.31%)
After Hours
71.47
+0.07(+0.10%)
- Real-time Data
  • Volume:
    116,451
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    70.88 - 72.17

ENTA Overview

Prev. Close
71.25
Day's Range
70.88-72.17
Revenue
97.12M
Open
72.17
52 wk Range
40.32-72.17
EPS
-4.16
Volume
116,451
Market Cap
1.44B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
147,431
P/E Ratio
-
Beta
0.45
1-Year Change
59.78%
Shares Outstanding
20,214,850
Next Earnings Date
Feb 09, 2022
What is your sentiment on Enanta Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Enanta Pharmaceuticals Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummarySellNeutralStrong BuyStrong BuyStrong Buy

Enanta Pharmaceuticals Inc Company Profile

Enanta Pharmaceuticals Inc Company Profile

Employees
141

Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.

Read More
  • Buy and hold...
    1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.